Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake

Commodore Capital exited 3,200,000 shares of Viridian Therapeutics. As a result, the net position value decreased by $69.06 million due to the complete share sale.

The Motley Fool • Feb 23, 2026

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 16,650 shares of the company's common stock to one new employee (the “In.

Business Wire • Jan 8, 2026

Viridian Therapeutics Prepares for Transformational 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company's key priorities and anticipated catalysts for 2026. “Following another year of strong execution across our portfolio, we enter 2026 positioned for meaningful value-creation and progress,” said Steve Mahoney, President and Chief Executive Officer of.

Business Wire • Jan 6, 2026

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for veligrotug for the treatment of thyroid eye disease (TED). The application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA.

Business Wire • Dec 22, 2025

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED).

Benzinga • Dec 15, 2025

Viridian Therapeutics Is Ready For An Eventful 2026

A slow period for Viridian Therapeutics, Inc. is coming to its conclusion. VRDN has recently completed financing transactions that put it on track to achieve profitability without additional dilution. Roche's Enspryng (satralizumab) has generated disappointing phase 3 results in thyroid eye disease patients, easing concerns about competition to veligrotug and VRDN-003 from the IL-6 antibody class.

Seeking Alpha • Nov 6, 2025

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025. “The Viridian team continues to deliver strong results, highlighted by the successful submission of our BLA for veligrotug, completing enrollment in both pivotal c.

Business Wire • Nov 5, 2025

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $1.15 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Nov 4, 2025

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successful October submission of its BLA to the U.S. Food and Drug Administration (FDA) for veligrotug, the company's investigational therapy for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disorder characterized by.

Business Wire • Nov 3, 2025